MARKET

XENE

XENE

Xenon Pharmaceut
NASDAQ
56.40
-0.69
-1.21%
Closed 17:36 04/21 EDT
OPEN
56.48
PREV CLOSE
57.09
HIGH
57.00
LOW
55.66
VOLUME
666.66K
TURNOVER
0
52 WEEK HIGH
63.95
52 WEEK LOW
28.19
MARKET CAP
5.38B
P/E (TTM)
-12.9221
1D
5D
1M
3M
1Y
5Y
1D
Xenon’s Azetukalner: Rapid, Durable Efficacy and Once‑Daily Convenience Underpin Buy Rating and Preferred Second‑Line Epilepsy Positioning
TipRanks · 1d ago
Weekly Report: what happened at XENE last week (0413-0417)?
Weekly Report · 1d ago
Reported Sunday, Xenon Presents Phase 3 X-TOLE2 Data Showing Azetukalner Delivers 53.2% Reduction In Monthly Seizure Frequency Versus 10.4% For Placebo In Focal Onset Seizures At AAN 2026
Benzinga · 2d ago
Analysts Are Bullish on Top Healthcare Stocks: Xenon (XENE), Biogen (BIIB)
TipRanks · 2d ago
Xenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study
TipRanks · 2d ago
Xenon says Phase 3 X-TOLE2 trial shows azetukalner cuts monthly seizures 53%
PUBT · 2d ago
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
Barchart · 2d ago
Xenon to Spotlight Neurology Pipeline at Series of 2026 Investor Conferences
TipRanks · 6d ago
More
About XENE
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.

Webull offers Xenon Pharmaceuticals Inc stock information, including NASDAQ: XENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XENE stock methods without spending real money on the virtual paper trading platform.